{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:00:28Z","timestamp":1789664428309,"version":"4.0.1"},"reference-count":16,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Technology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the safety, efficacy, and tolerability of zuranolone for the treatment of postpartum depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was conducted through PubMed using the following terms: zuranolone, postpartum depression, perinatal depression, SAGE-217, and allopregnanolone analogue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Articles describing the pharmacology, pharmacokinetics, efficacy, safety, and\/or tolerability of zuranolone were included in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>\n                      Zuranolone is an allopregnanolone analogue that works through modulation of the GABA\n                      <jats:sub>A<\/jats:sub>\n                      receptor. Clinical trials have demonstrated that compared with placebo, zuranolone is effective in treating patients with postpartum depression. Common adverse events associated with zuranolone include fatigue, somnolence, headache, dizziness, diarrhea, sedation, upper respiratory tract infection, and nausea.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Pharmacotherapeutic options to treat postpartum depression include selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, with the medication brexanolone (the first allopregnanolone analogue) reserved for severe postpartum depression. Zuranolone, the newest medication in its class, is without the same limitations as brexanolone, thus affording providers an additional easy-to-use option for treating postpartum depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/87551225241287383","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T08:05:21Z","timestamp":1728633921000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Zuranolone for the Treatment of Postpartum Depression"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-2906","authenticated-orcid":false,"given":"Erin","family":"St. Onge","sequence":"first","affiliation":[{"name":"Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chardae","family":"Whitner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"bibr1-87551225241287383","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"bibr2-87551225241287383","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50897"},{"key":"bibr3-87551225241287383","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005202"},{"key":"bibr4-87551225241287383","unstructured":"National Institutes of Health. Moms\u2019 Mental Health Matters. U.S. Department of Health and Human Services. Accessed June 4, 2024. https:\/\/www.nichd.nih.gov\/ncmhep\/initiatives\/moms-mental-health-matters\/moms"},{"key":"bibr5-87551225241287383","unstructured":"Association for Behavioral and Cognitive Therapies (ABCT). Postpartum Depression and Anxiety. Accessed June 4, 2024. https:\/\/www.abct.org\/fact-sheets\/postpartum-depression-and-anxiety\/#:~:text=Cognitive%20behavioral%20therapy%20(CBT)%20is,thoughts%2C%20feelings%2C%20and%20behaviors"},{"key":"bibr6-87551225241287383","doi-asserted-by":"publisher","DOI":"10.1176\/appi.prcp.20210001"},{"key":"bibr7-87551225241287383","unstructured":"Sage Therapeutics Inc. Zulresso (brexanolone) [package insert]. U.S. Food and Drug Administration Website. Accessed May 15, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211371lbl.pdf"},{"key":"bibr8-87551225241287383","unstructured":"GoodRx Inc. Zulresso. GoodRx Website. Accessed August 2, 2024. https:\/\/www.goodrx.com\/zulresso."},{"key":"bibr9-87551225241287383","unstructured":"Sage Therapeutics Inc. Zurzuvae (zuranolone) [package insert]. U.S. Food and Drug Administration Website. Accessed May 15, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217369s000lbl.pdf."},{"key":"bibr10-87551225241287383","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14445"},{"key":"bibr11-87551225241287383","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333"},{"key":"bibr12-87551225241287383","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1559"},{"key":"bibr13-87551225241287383","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220785"},{"key":"bibr14-87551225241287383","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14475"},{"key":"bibr15-87551225241287383","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14845"},{"key":"bibr16-87551225241287383","unstructured":"GoodRx Inc. Zurzuvae. GoodRx Website. Accessed August 2, 2024. https:\/\/www.goodrx.com\/zuranolone."}],"container-title":["Journal of Pharmacy Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225241287383","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/87551225241287383","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/87551225241287383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:32:51Z","timestamp":1777602771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/87551225241287383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/87551225241287383"],"URL":"https:\/\/doi.org\/10.1177\/87551225241287383","relation":{},"ISSN":["8755-1225","1549-4810"],"issn-type":[{"value":"8755-1225","type":"print"},{"value":"1549-4810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}